Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

被引：9
|
作者：
Liam, Chong-Kin [1 ]
机构：
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur 50603, Malaysia
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2017年 / 6卷
关键词：
SINGLE-ARM; AZD9291; MULTICENTER; RESISTANCE; MUTATIONS; ERLOTINIB; TKI;
D O I：
10.21037/tlcr.2017.10.10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S62 / S66
页数：5
相关论文
共 50 条
  • [21] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    [J]. CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [22] The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment
    Li, Jisheng
    Zhao, Wen
    Li, Hongxin
    Xuan, Tiantian
    Wang, Chengjun
    Zhang, Rongyu
    Yang, Chuang
    Wang, Jian
    Yi, Cuihua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Tsuji, F.
    Rosell, R.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Sbar, E.
    Wang, T.
    Zhang, H.
    Mok, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754
  • [24] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Sequist, Lecia V.
    Martins, Renato G.
    Spigel, David
    Grunberg, Steven M.
    Spira, Alexander
    Jaenne, Pasi A.
    Joshi, Victoria A.
    McCollum, David
    Evans, Tracey L.
    Muzikansky, Alona
    Kuhlmann, Georgiana L.
    Han, Moon
    Goldberg, Jonathan S.
    Settleman, Jeffrey
    Iafrate, A. John
    Engelman, Jeffrey A.
    Haber, Daniel A.
    Johnson, Bruce E.
    Lynch, Thomas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449
  • [25] BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS
    Westerink, L.
    Nicolai, J.
    Samuelsen, C. H.
    Griebsch, I
    Postma, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S472 - S472
  • [26] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    [J]. JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [27] First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
    Nguyen, Kim-Son H.
    Neal, Joel W.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 337 - 345
  • [28] Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
    Adderley, Helen
    Ackermann, Christoph Jakob
    Califano, Raffaele
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [29] Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study
    Wang, Pingli
    Li, Yuping
    Lv, Dongqing
    Yang, Lingge
    Ding, Liren
    Zhou, Jianya
    Hong, Wei
    Chen, Youfei
    Zhang, Dongqing
    He, Susu
    Zhou, Jianying
    Wang, Kai
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [30] Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study
    Pingli Wang
    Yuping Li
    Dongqing Lv
    Lingge Yang
    Liren Ding
    Jianya Zhou
    Wei Hong
    Youfei Chen
    Dongqing Zhang
    Susu He
    Jianying Zhou
    Kai Wang
    [J]. Signal Transduction and Targeted Therapy, 6
12345